In contrast to chemotherapy, CDK4/6 inhibitor-associated neutropenia is rapidly reversible, as CDK4/6 inhibitors induce cell-cycle arrest by decreasing the proliferation of hematopoietic stem cells, with resumed proliferation following a CDK4/6 dose reduction or interruption [52]. The gene discussed is CDK4; the disease is neutropenia.